Tata Capital acquires stake in Biocon Biologics

0
1371
Krishnamurthy & Co Shwetambari Rao Platinum Partners K Law
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Krishnamurthy & Co (K Law) advised Biocon Biologics India when Tata Capital acquired a 0.85% stake in it for ₹2.25 billion (US$30 million). Platinum Partners advised Tata Capital, which invested through Tata Capital Growth Fund II.

Biocon Biologics India is a subsidiary of Biocon, a listed biopharmaceuticals company.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link